FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trialVolker Heinemann, Sebastian Stintzing, Christoph Kahl et al.|The Lancet Oncology|2014Cited by 1.7k
Prävention, Diagnostik, Therapie und Nachsorge des LungenkarzinomsG. Goeckenjan, Hans‐Ulrich Kauczor, H. Sitter et al.|Pneumologie|2010Cited by 166
Prevention, Diagnosis, Therapy, and Follow-up of Lung CancerG. Goeckenjan, Hans‐Ulrich Kauczor, H. Sitter et al.|Pneumologie|2010Cited by 150
Prävention, Diagnostik, Therapie und Nachsorge des LungenkarzinomsG. Goeckenjan, Hans‐Ulrich Kauczor, H. Sitter et al.|Pneumologie|2011Cited by 79